Catalyst

Slingshot members are tracking this event:

Mylan (MYL) and Biocon Submit Biologics License Application (BLA) to FDA for Biosimilar to Roche's (RHHBY) Herceptin for HER2-Positive Breast and Gastric Cancers

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
MYL

100%
RHHBY

100%
Biocon Ltd.

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 08, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Biologics License Application, Bla, Fda, Biosimilar, Herceptin, Her2-positive Breast Cancer, Gastric Cancers